(19)
(11) EP 4 798 599 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 25705458.5

(22) Date of filing: 14.01.2025
(51) International Patent Classification (IPC): 
C07H 19/14(2006.01)
A61K 31/7064(2006.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07H 19/14
(86) International application number:
PCT/CZ2025/050002
(87) International publication number:
WO 2026/153596 (23.07.2026 Gazette 2026/30)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(71) Applicant: Ustav Organicke Chemie a Biochemie AV CR v.v.i.
16000 Praha 6 (CZ)

(72) Inventors:
  • TICHY, Michal
    25069 Vodochody (CZ)
  • HOCEK, Michal
    16000 Praha 6 (CZ)
  • SINKEVICIUTE, Ugne
    10000 Praha 10 (CZ)
  • SACHA, Pavel
    16300 Praha 6 (CZ)
  • ORMSBY, Tereza
    12000 Praha 2 (CZ)
  • SIMOVA, Magdalena
    16100 Praha 6 (CZ)
  • BLAZKOVA, Kristyna
    15300 Praha 5 (CZ)
  • KONVALINKA, Jan
    16100 Praha 6 (CZ)

(74) Representative: Harber IP s.r.o. 
Dukelskych hrdinu 567/52
17000 Praha 7
17000 Praha 7 (CZ)

   


(54) 6-(HET)ARYL-7-DEAZAPURINE RIBONUCLEOSIDE BISPHOSPHONATES AS CD73 INHIBITORS FOR CLINICAL USE